Immunocore Current Deferred Revenue vs Accounts Payable Analysis

IMCR Stock

USD 32.28 0.16 0.50%

Immunocore Holdings financial indicator trend analysis is infinitely more than just investigating Immunocore Holdings recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunocore Holdings is a good investment. Please check the relationship between Immunocore Holdings Current Deferred Revenue and its Accounts Payable accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunocore Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.

Current Deferred Revenue vs Accounts Payable

Current Deferred Revenue vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunocore Holdings Current Deferred Revenue account and Accounts Payable. At this time, the significance of the direction appears to have pay attention.

The correlation between Immunocore Holdings' Current Deferred Revenue and Accounts Payable is -0.74. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Immunocore Holdings, assuming nothing else is changed. The correlation between historical values of Immunocore Holdings' Current Deferred Revenue and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Immunocore Holdings are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Current Deferred Revenue i.e., Immunocore Holdings' Current Deferred Revenue and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.74

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Accounts Payable

An accounting item on the balance sheet that represents Immunocore Holdings obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Immunocore Holdings are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Immunocore Holdings' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunocore Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunocore Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.At this time, Immunocore Holdings' Tax Provision is relatively stable compared to the past year. As of 11/25/2024, Enterprise Value is likely to grow to about 3.1 B, while Selling General Administrative is likely to drop slightly above 84.5 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	7.6M	5.3M	4.1M	5.8M
Interest Income	47K	3.2M	12.5M	13.1M

Depreciation And Amortization Interest Income

Immunocore Holdings fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Other Stockholder Equity	Total Current Assets	Property Plant Equipment	Other Current Assets	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Total Liab
Other Current Liab		0.76	-0.4	0.69	-0.91	0.65	0.23	0.59	0.91	0.76	0.43	0.09	0.84	0.73	0.95	0.48	-0.93	0.83	0.67	0.32	0.75	0.83	0.84	-0.59	0.5	0.74
Total Current Liabilities	0.76		-0.18	0.33	-0.85	0.95	0.32	0.83	0.84	0.75	0.8	0.55	0.85	0.9	0.73	0.81	-0.65	0.79	0.94	0.24	0.92	0.79	0.81	-0.39	-0.01	0.87
Other Liab	-0.4	-0.18		-0.77	0.37	-0.19	-0.32	0.2	-0.43	-0.54	0.02	0.22	-0.53	-0.38	-0.59	-0.05	0.61	-0.58	-0.21	0.04	-0.37	-0.58	-0.59	0.46	-0.47	-0.25
Net Tangible Assets	0.69	0.33	-0.77		-0.48	0.24	0.08	0.15	0.7	0.77	-0.12	-0.42	0.74	0.34	0.84	0.02	-0.9	0.76	0.25	0.3	0.36	0.76	0.67	-0.46	0.79	0.5
Retained Earnings	-0.91	-0.85	0.37	-0.48		-0.79	-0.28	-0.64	-0.86	-0.66	-0.69	-0.43	-0.78	-0.89	-0.85	-0.73	0.77	-0.75	-0.85	-0.12	-0.9	-0.75	-0.84	0.63	-0.14	-0.76
Accounts Payable	0.65	0.95	-0.19	0.24	-0.79		0.49	0.8	0.8	0.62	0.89	0.65	0.75	0.89	0.66	0.86	-0.56	0.69	0.92	0.18	0.91	0.69	0.75	-0.47	-0.15	0.77
Other Assets	0.23	0.32	-0.32	0.08	-0.28	0.49		0.23	0.28	0.17	0.42	0.12	0.29	0.29	0.26	0.2	-0.24	0.29	0.25	0.05	0.29	0.29	0.3	-0.18	0.06	0.21
Net Receivables	0.59	0.83	0.2	0.15	-0.64	0.8	0.23		0.68	0.53	0.65	0.43	0.62	0.57	0.52	0.65	-0.48	0.54	0.72	0.22	0.6	0.54	0.51	-0.21	-0.07	0.76
Other Stockholder Equity	0.91	0.84	-0.43	0.7	-0.86	0.8	0.28	0.68		0.81	0.56	0.24	0.89	0.81	0.96	0.6	-0.91	0.87	0.75	0.27	0.83	0.87	0.9	-0.7	0.37	0.76
Total Current Assets	0.76	0.75	-0.54	0.77	-0.66	0.62	0.17	0.53	0.81		0.24	-0.04	0.98	0.66	0.85	0.32	-0.88	0.98	0.58	0.22	0.67	0.98	0.88	-0.33	0.55	0.75
Property Plant Equipment	0.43	0.8	0.02	-0.12	-0.69	0.89	0.42	0.65	0.56	0.24		0.89	0.41	0.83	0.38	0.94	-0.22	0.34	0.88	0.06	0.83	0.34	0.5	-0.44	-0.5	0.55
Other Current Assets	0.09	0.55	0.22	-0.42	-0.43	0.65	0.12	0.43	0.24	-0.04	0.89		0.09	0.65	0.04	0.84	0.14	0.04	0.69	-0.22	0.64	0.04	0.26	-0.34	-0.79	0.23
Total Assets	0.84	0.85	-0.53	0.74	-0.78	0.75	0.29	0.62	0.89	0.98	0.41	0.09		0.77	0.9	0.46	-0.9	0.99	0.7	0.25	0.78	0.99	0.92	-0.42	0.46	0.82
Short Long Term Debt Total	0.73	0.9	-0.38	0.34	-0.89	0.89	0.29	0.57	0.81	0.66	0.83	0.65	0.77		0.74	0.85	-0.62	0.74	0.92	0.07	1.0	0.74	0.86	-0.62	-0.08	0.69
Total Stockholder Equity	0.95	0.73	-0.59	0.84	-0.85	0.66	0.26	0.52	0.96	0.85	0.38	0.04	0.9	0.74		0.45	-0.98	0.9	0.64	0.28	0.76	0.9	0.91	-0.67	0.55	0.72
Property Plant And Equipment Net	0.48	0.81	-0.05	0.02	-0.73	0.86	0.2	0.65	0.6	0.32	0.94	0.84	0.46	0.85	0.45		-0.29	0.38	0.95	0.19	0.86	0.38	0.51	-0.41	-0.46	0.69
Net Debt	-0.93	-0.65	0.61	-0.9	0.77	-0.56	-0.24	-0.48	-0.91	-0.88	-0.22	0.14	-0.9	-0.62	-0.98	-0.29		-0.91	-0.53	-0.3	-0.64	-0.91	-0.87	0.58	-0.68	-0.69
Cash	0.83	0.79	-0.58	0.76	-0.75	0.69	0.29	0.54	0.87	0.98	0.34	0.04	0.99	0.74	0.9	0.38	-0.91		0.63	0.17	0.75	1.0	0.94	-0.46	0.52	0.73
Non Current Assets Total	0.67	0.94	-0.21	0.25	-0.85	0.92	0.25	0.72	0.75	0.58	0.88	0.69	0.7	0.92	0.64	0.95	-0.53	0.63		0.26	0.94	0.63	0.69	-0.41	-0.21	0.84
Non Currrent Assets Other	0.32	0.24	0.04	0.3	-0.12	0.18	0.05	0.22	0.27	0.22	0.06	-0.22	0.25	0.07	0.28	0.19	-0.3	0.17	0.26		0.1	0.17	-0.03	0.25	0.34	0.55
Long Term Debt	0.75	0.92	-0.37	0.36	-0.9	0.91	0.29	0.6	0.83	0.67	0.83	0.64	0.78	1.0	0.76	0.86	-0.64	0.75	0.94	0.1		0.75	0.86	-0.61	-0.06	0.73
Cash And Short Term Investments	0.83	0.79	-0.58	0.76	-0.75	0.69	0.29	0.54	0.87	0.98	0.34	0.04	0.99	0.74	0.9	0.38	-0.91	1.0	0.63	0.17	0.75		0.94	-0.46	0.52	0.73
Common Stock Shares Outstanding	0.84	0.81	-0.59	0.67	-0.84	0.75	0.3	0.51	0.9	0.88	0.5	0.26	0.92	0.86	0.91	0.51	-0.87	0.94	0.69	-0.03	0.86	0.94		-0.7	0.35	0.63
Non Current Liabilities Total	-0.59	-0.39	0.46	-0.46	0.63	-0.47	-0.18	-0.21	-0.7	-0.33	-0.44	-0.34	-0.42	-0.62	-0.67	-0.41	0.58	-0.46	-0.41	0.25	-0.61	-0.46	-0.7		-0.12	-0.13
Inventory	0.5	-0.01	-0.47	0.79	-0.14	-0.15	0.06	-0.07	0.37	0.55	-0.5	-0.79	0.46	-0.08	0.55	-0.46	-0.68	0.52	-0.21	0.34	-0.06	0.52	0.35	-0.12		0.18
Total Liab	0.74	0.87	-0.25	0.5	-0.76	0.77	0.21	0.76	0.76	0.75	0.55	0.23	0.82	0.69	0.72	0.69	-0.69	0.73	0.84	0.55	0.73	0.73	0.63	-0.13	0.18

Click cells to compare fundamentals

Immunocore Holdings Account Relationship Matchups

Immunocore Holdings fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	5.1M	36.5M	45.8M	58.1M	114.3M	120.0M
Total Current Liabilities	84.5M	55.0M	61.2M	83.1M	139.0M	72.0M
Other Liab	48.1M	25.0M	6.5M	5.9M	5.3M	5.1M
Net Tangible Assets	14.8M	55.3M	171.5M	278.3M	320.1M	336.1M
Retained Earnings	(279.1M)	(349.9M)	(481.4M)	(261.3M)	(744.7M)	(707.4M)
Accounts Payable	15.7M	7.9M	10.1M	14.5M	17.8M	11.5M
Other Assets	6.5M	7.2M	7.5M	11.6M	10.4M	7.5M
Net Receivables	50.0M	2.1M	24.8M	27.8M	61.4M	33.1M
Other Stockholder Equity	293.9M	20.1M	494.9M	1.0B	1.1B	1.2B
Total Current Assets	124.3M	152.9M	262.7M	391.9M	528.8M	270.4M
Property Plant Equipment	54.9M	36.8M	31.5M	31.6M	36.4M	33.1M
Other Current Assets	48.8M	27.7M	26.5M	13.7M	9.7M	9.2M
Total Assets	185.6M	197.2M	301.8M	435.5M	597.0M	350.7M
Short Long Term Debt Total	59.4M	63.9M	63.8M	69.3M	84.0M	65.9M
Total Stockholder Equity	14.8M	55.3M	171.5M	278.8M	368.8M	387.3M
Property Plant And Equipment Net	54.9M	36.8M	31.5M	31.6M	42.7M	40.1M
Net Debt	(14.6M)	(65.8M)	(174.1M)	(263.2M)	(358.6M)	(340.7M)
Cash	74.0M	129.7M	237.9M	332.5M	442.6M	245.9M
Non Current Assets Total	61.4M	44.3M	39.0M	43.6M	68.2M	51.5M
Non Currrent Assets Other	4.4M	4.2M	(31.5M)	7.2M	14.5M	15.2M
Cash And Short Term Investments	74.0M	129.7M	237.9M	332.5M	442.6M	245.9M
Liabilities And Stockholders Equity	185.6M	197.2M	301.8M	435.5M	597.0M	350.7M
Non Current Liabilities Total	86.4M	86.9M	69.0M	73.7M	89.1M	66.0M
Capital Lease Obligations	40.3M	27.2M	26.6M	29.8M	36.0M	29.3M
Inventory	(48.6M)	(21.2M)	(18.8M)	943K	4.5M	4.7M
Total Liab	170.9M	141.8M	130.2M	156.8M	228.2M	177.3M
Net Invested Capital	33.9M	92M	208.8M	318.3M	416.9M	210.0M
Long Term Investments	591K	973K	165K	137K	123.3K	117.1K
Property Plant And Equipment Gross	54.9M	36.8M	31.5M	31.6M	95.0M	49.7M
Accumulated Other Comprehensive Income	(32K)	163K	386.3M	334.8M	(36.3M)	(34.4M)
Net Working Capital	39.8M	97.9M	201.5M	308.8M	389.8M	212.6M

Pair Trading with Immunocore Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving against Immunocore Stock

0.35

KZR

Kezar Life Sciences

Pair Corr

The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.

The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Immunocore Stock Analysis

When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC